These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 10699384)

  • 1. Protease inhibitors. Part 7. Inhibition of Clostridium histolyticum collagenase with sulfonylated derivatives of L-valine hydroxamate.
    Supuran CT; Scozzafava A
    Eur J Pharm Sci; 2000 Mar; 10(1):67-76. PubMed ID: 10699384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protease inhibitors: Synthesis of L-alanine hydroxamate sulfonylated derivatives as inhibitors of clostridium histolyticum collagenase.
    Supuran CT; Briganti F; Mincione G; Scozzafava A
    J Enzyme Inhib; 2000; 15(2):111-28. PubMed ID: 10938538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protease inhibitors. Part 8: synthesis of potent Clostridium histolyticum collagenase inhibitors incorporating sulfonylated L-alanine hydroxamate moieties.
    Scozzafava A; Supuran CT
    Bioorg Med Chem; 2000 Mar; 8(3):637-45. PubMed ID: 10732980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protease inhibitors - part 5. Alkyl/arylsulfonyl- and arylsulfonylureido-/arylureido- glycine hydroxamate inhibitors of Clostridium histolyticum collagenase.
    Scozzafava A; Supuran CT
    Eur J Med Chem; 2000 Mar; 35(3):299-307. PubMed ID: 10785556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.
    Scozzafava A; Supuran CT
    J Med Chem; 2000 May; 43(9):1858-65. PubMed ID: 10794702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protease inhibitors. Part 12. Synthesis of potent matrix metalloproteinase and bacterial collagenase inhibitors incorporating sulfonylated N-4-nitrobenzyl-beta-alanine hydroxamate moieties.
    Scozzafava A; Ilies MA; Manole G; Supuran CT
    Eur J Pharm Sci; 2000 Jul; 11(1):69-79. PubMed ID: 10913755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protease inhibitors: synthesis of a series of bacterial collagenase inhibitors of the sulfonyl amino acyl hydroxamate type.
    Clare BW; Scozzafava A; Supuran CT
    J Med Chem; 2001 Jun; 44(13):2253-8. PubMed ID: 11405662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protease inhibitors: synthesis of clostridium histolyticum collagenase inhibitors incorporating sulfonyl-L-alanine hydroxamate moieties.
    Scozzafava A; Supuran CT
    Bioorg Med Chem Lett; 2000 Mar; 10(5):499-502. PubMed ID: 10743957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.
    Scozzafava A; Supuran CT
    J Med Chem; 2000 Oct; 43(20):3677-87. PubMed ID: 11020282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions.
    Scozzafava A; Supuran CT
    Bioorg Med Chem Lett; 2002 Oct; 12(19):2667-72. PubMed ID: 12217351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protease inhibitors: synthesis of bacterial collagenase and matrix metalloproteinase inhibitors incorporating arylsulfonylureido and 5-dibenzo-suberenyl/suberyl moieties.
    Ilies M; Banciu MD; Scozzafava A; Ilies MA; Caproiu MT; Supuran CT
    Bioorg Med Chem; 2003 May; 11(10):2227-39. PubMed ID: 12713832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A quantitative structure-activity relationship study on Clostridium histolyticum collagenase inhibitors: roles of electrotopological state indices.
    Gupta SP; Kumaran S
    Bioorg Med Chem; 2003 Jul; 11(14):3065-71. PubMed ID: 12818668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protease inhibitors: synthesis of bacterial collagenase and matrix metalloproteinase inhibitors incorporating succinyl hydroxamate and iminodiacetic acid hydroxamate moieties.
    Santos MA; Marques S; Gil M; Tegoni M; Scozzafava A; Supuran CT
    J Enzyme Inhib Med Chem; 2003 Jun; 18(3):233-42. PubMed ID: 14506914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative QSAR study on carbonic anhydrase and matrix metalloproteinase inhibition by sulfonylated amino acid hydroxamates.
    Gupta SP; Maheswaran V; Pande V; Kumar D
    J Enzyme Inhib Med Chem; 2003 Feb; 18(1):7-13. PubMed ID: 12751815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A quantitative structure-activity relationship study on some matrix metalloproteinase and collagenase inhibitors.
    Kumar D; Gupta SP
    Bioorg Med Chem; 2003 Feb; 11(3):421-6. PubMed ID: 12517437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.
    Hanessian S; Moitessier N; Gauchet C; Viau M
    J Med Chem; 2001 Sep; 44(19):3066-73. PubMed ID: 11543675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vertebrate collagenase inhibitor. II. Tetrapeptidyl hydroxamic acids.
    Odake S; Okayama T; Obata M; Morikawa T; Hattori S; Hori H; Nagai Y
    Chem Pharm Bull (Tokyo); 1991 Jun; 39(6):1489-94. PubMed ID: 1657422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide hydroxamic acids inhibit skin collagenase.
    Moore WM; Spilburg CA
    Biochem Biophys Res Commun; 1986 Apr; 136(1):390-5. PubMed ID: 3010973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and structure-activity relationships of second-generation hydroxamate botulinum neurotoxin A protease inhibitors.
    Capková K; Yoneda Y; Dickerson TJ; Janda KD
    Bioorg Med Chem Lett; 2007 Dec; 17(23):6463-6. PubMed ID: 17951059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailability.
    Hajduk PJ; Shuker SB; Nettesheim DG; Craig R; Augeri DJ; Betebenner D; Albert DH; Guo Y; Meadows RP; Xu L; Michaelides M; Davidsen SK; Fesik SW
    J Med Chem; 2002 Dec; 45(26):5628-39. PubMed ID: 12477346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.